Oric Pharma Reports New Inducement Grants Under Nasdaq Rule
ORIC Pharmaceuticals has granted 292,500 non-qualified stock options and 79,000 restricted stock units to a newly hired, non-executive officer...
No videos found.
Amgen’s New Study Reveals Rocatinlimab’s Phase 3 Results
Amgen and Kyowa Kirin released preliminary top-line findings from ASCEND, the long-term extension of their global Phase 3 ROCKET...
Nurexone’s Breakthrough Patent Secures Exosome Supply Chain
Nurexone Biologic has received a US Notice of Allowance for a patent covering its proprietary exosome manufacturing process, built...
EU Approves Oral Semaglutide to Reduce Cardiovascular Death
Novo Nordisk has secured a European label update for Rybelsus (oral semaglutide) to include cardiovascular risk reduction based on...
Harrow Reveals Agenda, Speakers for Investor & Analyst Day
Harrow has set September 26 in New York for its Investor & Analyst Day, previewing a full-throated update across...
INmune Bio’s Successful First Commercial Run of Cordstrom™
INmune Bio has completed its first full-scale pilot commercial manufacturing run of CordSTROM, an off-the-shelf, allogeneic mesenchymal stromal cell...
Krystal Biotech’s Vyjuvek® Label Updated by FDA Approval
FDA has cleared a label update for Krystal Biotech’s Vyjuvek, expanding eligibility to all dystrophic epidermolysis bullosa patients from...
Monte Rosa, Novartis Collaborate on New Immune Degraders
Novartis has expanded its relationship with Monte Rosa Therapeutics, securing an exclusive license to an undisclosed discovery-stage target and...
Successful Ryoncil® Launch Spotlighted at Global Conferences
Mesoblast has put a commercial stake in the ground with the U.S. launch of Ryoncil (remestemcel‑l‑rknd), the first and...
Teva’s MSA Drug Emrusolmin Gets FDA Fast Track Designation
Teva’s emrusolmin (TEV-56286), a small-molecule modulator of pathogenic alpha-synuclein oligomers, has received FDA Fast Track designation for multiple system...